Bristol-Myers Squibb, NYSE

Bristol-Myers Squibb (NYSE:BMY) Position Increased by Legacy Private Trust Co.
Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC).
Should Bristol-Myers Squibb Company (NYSE:BMY) Be In Your Early Retirement Portfolio?
We recently compiled a list of the Early Retirement Portfolio: 10 Stocks to Live Off Dividends. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other stocks.
Bristol-Myers Squibb Co (BMY) Stock: Greater Than Its Current Valuation?
Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the stock to Neutral,
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bristol-Myers Squibb's whale activity within a strike price range from $43.0 to $75.0 in the last 30 days.
Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY)
In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research
Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet
Failed to fetch dynamically imported module: https://uk.finance.yahoo.com/assets/_app/immutable/nodes/96.Cy8eSqq3.js
Bristol Myers Squibb Co. stock rises Monday, still underperforms market
Bristol Myers Squibb Co. closed $4.40 below its 52-week high ($61.08), which the company achieved on November 11th.
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day
The stock's fall snapped a two-day winning streak.
Bristol Myers to report Q4 IPRD/licensing expense of $18M
Bristol Myers Squibb (NYSE:BMY) said it expects to report a Q4 net expense of $18M related to acquired IPRD and licensing ...
Yahoo Finance3d
Bristol-Myers Squibb Company (BMY)
In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other stocks. As retirement approaches, ensuring financial stability becomes ...
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors despite daily gains
This was the stock's second consecutive day of gains.
Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval
Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...
This Unpopular Dividend Stock Is a Buy
This double-digit growth in new drug sales showcases the company's ability to successfully commercialize cutting-edge ...
Baylor College of Medicine3d
Baylor College of Medicine
Texas Children’s Global HOPE and Baylor College of Medicine Global Health, with support from the Bristol Myers Squibb ...